Abstract 4039
Background
The aim of this study was to assess the prognostic significance of parameters derived from pretreatmentF-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) for patients with nasopharyngeal carcinoma (NPC) received intensity-modulated radiation therapy (IMRT). Furthermore, the functional information provided by PET/CT may offer the feasibility of biological conformality in tumor target delineation and dose planning.
Methods
We retrospectively reviewed 82 NPC patients who underwent pretreatment F-18 FDG PET/CT and received IMRT between 2010 and 2013. Maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) of the primary tumor were measured by F-18 FDG PET/CT. MTV might be viewed as a collection of absolute SUV values equal to or greater than a certain threshold on each axial image of PET/CT. The ROC curve was used to determine the appropriate cut-off point of SUVmax and MTV. The prognostic significance of MTV, SUVmax was assessed in the study. Meanwhile, the paper studies the relation between SUVmax, MTV, and primary tumor volume (PTV). Receiver operating characteristic (ROC) analysis was used to determine the optimal MTV cut-off value.
Results
Positive correlations between PTV and MTV, SUVmax and MTV were found. PTV, SUVmax, and MTV were significant predictors of survival. The 3-year progression-free survival (PFS) for SUVmax≤8.20 and SUVmax>8.20 were 91.1% and 73.0% (p = 0.027). With furthermore analysis, patients having tumor with lower MTV had higher 3-year PFS than patients having tumor with higher MTV. The percentage of the MTV5.0 in PTV was 14.66±15.75% (95%CI,11.20-18.13).
Conclusions
Our study indicated that PET/CT-derived parameters, SUVmax and MTV, are very important in assessing prognosis and making radiotherapy planning. Patients having tumor with lower MTV had higher 3-year PFS than patients having tumor with higher MTV. It is necessary to give a more aggressive treatment for patients with higher MTV. The MTV5.0 might be an appropriate quantitative definition of hypoxic sub-volumes for radiotherapy boost to improve the therapeutic effect.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract